BLPH
Income statement / Annual
Last year (2022), Bellerophon Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Bellerophon Therapeutics, Inc.'s net income was -$19.83 M.
See Bellerophon Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$65.00 K
|
$102.00 K
|
$147.00 K
|
$348.00 K
|
$362.00 K
|
$373.00 K
|
$400.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$65.00 K
|
-$102.00 K
|
-$147.00 K
|
-$348.00 K
|
-$362.00 K
|
-$373.00 K
|
-$400.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$16.36 M
|
$13.02 M
|
$17.89 M
|
$11.03 M
|
$20.26 M
|
$17.85 M
|
$16.65 M
|
$33.37 M
|
$45.98 M
|
$52.99 M
|
| General & Administrative Expenses |
$6.02 M
|
$7.15 M
|
$8.39 M
|
$6.44 M
|
$7.62 M
|
$6.75 M
|
$7.11 M
|
$14.87 M
|
$0.00
|
$9.01 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.02 M
|
$7.15 M
|
$8.39 M
|
$6.44 M
|
$7.62 M
|
$6.75 M
|
$7.11 M
|
$14.87 M
|
$13.78 M
|
$9.01 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$674.00 K
|
$27.88 M
|
$24.60 M
|
$23.76 M
|
$48.24 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$22.38 M
|
$20.16 M
|
$26.28 M
|
$17.47 M
|
$27.88 M
|
$24.60 M
|
$23.76 M
|
$46.57 M
|
$59.75 M
|
$62.00 M
|
| Cost And Expenses |
$22.38 M
|
$20.16 M
|
$26.28 M
|
$17.47 M
|
$27.88 M
|
$24.60 M
|
$23.76 M
|
$46.57 M
|
$59.75 M
|
$62.00 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$378.00 K
|
$184.00 K
|
$95.00 K
|
$109.00 K
|
$79.00 K
|
$0.00
|
| Interest Expense |
$135.00 K
|
$5.00 K
|
$250.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$65.00 K
|
$102.00 K
|
$147.00 K
|
$348.00 K
|
$362.00 K
|
$373.00 K
|
$400.00 K
|
$377.00 K
|
$388.00 K
|
$429.00 K
|
| EBITDA |
-$22.18 M |
-$20.16 M |
-$26.71 M |
-$14.72 M |
-$2.26 M |
-$54.45 M |
-$23.85 M |
-$46.08 M |
-$59.37 M |
-$61.57 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$136.00 K
|
$605.00 K
|
-$577.00 K
|
$2.41 M
|
$25.26 M
|
-$30.22 M
|
-$495.00 K
|
$402.00 K
|
$79.00 K
|
$0.00
|
| Income Before Tax |
-$22.25 M
|
-$19.56 M
|
-$26.85 M
|
-$15.07 M
|
-$2.63 M
|
-$54.82 M
|
-$24.25 M
|
-$46.46 M
|
-$59.67 M
|
-$62.00 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$2.42 M
|
-$1.80 M
|
-$2.13 M
|
-$1.80 M
|
-$5.44 M
|
$0.00
|
-$438.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$19.83 M
|
-$17.76 M
|
-$24.73 M
|
-$13.27 M
|
$2.81 M
|
-$54.82 M
|
-$23.81 M
|
-$46.46 M
|
-$59.67 M
|
-$62.00 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.08 |
-1.87 |
-3.17 |
-2.95 |
0.65 |
-21.11 |
-3.17 |
-6.18 |
-5.01 |
-4.8 |
| EPS Diluted |
-2.08 |
-1.87 |
-3.17 |
-2.95 |
0.65 |
-21.11 |
-3.17 |
-6.18 |
-5.01 |
-4.8 |
| Weighted Average Shares Out |
$9.55 M
|
$9.50 M
|
$7.80 M
|
$4.50 M
|
$4.34 M
|
$2.60 M
|
$7.52 M
|
$7.52 M
|
$11.91 M
|
$12.91 M
|
| Weighted Average Shares Out Diluted |
$9.55 M
|
$9.50 M
|
$7.80 M
|
$4.50 M
|
$4.34 M
|
$2.60 M
|
$7.52 M
|
$7.52 M
|
$11.91 M
|
$12.91 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
